{"title":"低血糖意识受损","authors":"S. Amiel","doi":"10.15277/bjd.2022.358","DOIUrl":null,"url":null,"abstract":"Impaired awareness of hypoglycaemia (IAH), defined either clinically as the loss of subjective awareness of hypoglycaemia before the onset of cognitive impairment or biochemically as the loss of symptom perception until plasma glucose has fallen below 3 mmol/L (54 mg/dl), is the major modifiable risk factor for severe hypoglycaemia in T1DM and possibly in insulin-treated T2DM. This paper tells the story of IAH, its pathogenesis and its implications and the treatment strategies used to address it.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Impaired awareness of hypoglycaemia\",\"authors\":\"S. Amiel\",\"doi\":\"10.15277/bjd.2022.358\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Impaired awareness of hypoglycaemia (IAH), defined either clinically as the loss of subjective awareness of hypoglycaemia before the onset of cognitive impairment or biochemically as the loss of symptom perception until plasma glucose has fallen below 3 mmol/L (54 mg/dl), is the major modifiable risk factor for severe hypoglycaemia in T1DM and possibly in insulin-treated T2DM. This paper tells the story of IAH, its pathogenesis and its implications and the treatment strategies used to address it.\",\"PeriodicalId\":42951,\"journal\":{\"name\":\"British Journal of Diabetes\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-12-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15277/bjd.2022.358\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15277/bjd.2022.358","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Impaired awareness of hypoglycaemia (IAH), defined either clinically as the loss of subjective awareness of hypoglycaemia before the onset of cognitive impairment or biochemically as the loss of symptom perception until plasma glucose has fallen below 3 mmol/L (54 mg/dl), is the major modifiable risk factor for severe hypoglycaemia in T1DM and possibly in insulin-treated T2DM. This paper tells the story of IAH, its pathogenesis and its implications and the treatment strategies used to address it.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
